Zimmer Biomet Valuation Multiples

Zimmer Biomet Overview

About Zimmer Biomet

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Founded

2001

HQ

Employees

17.0K

Website

zimmerbiomet.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $8B

EBITDA: $3B

EV

$25B

Valuation Multiples

Multiples.vc

Start free trial

Zimmer Biomet Financials

Zimmer Biomet reported last 12-month revenue of $8B and EBITDA of $3B.

In the same LTM period, Zimmer Biomet generated $6B in gross profit, $3B in EBITDA, and $2B in net income.

Zimmer Biomet P&L

In the most recent fiscal year, Zimmer Biomet reported revenue of $8B and EBITDA of $3B.

Zimmer Biomet expects next 12-month revenue of XXX and NTM EBITDA of XXX

Zimmer Biomet Stock Performance

Zimmer Biomet has current market cap of $18B, and enterprise value of $25B.

Zimmer Biomet's stock price is $94.78.

Zimmer Biomet Valuation Multiples

Zimmer Biomet trades at 3.0x EV/Revenue multiple, and 9.2x EV/EBITDA.

Zimmer Biomet Financial Valuation Multiples

As of April 19, 2026, Zimmer Biomet has market cap of $18B and EV of $25B.

Equity research analysts estimate Zimmer Biomet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zimmer Biomet has a P/E ratio of 11.2x.

Zimmer Biomet Margins & Growth Rates

Zimmer Biomet's revenue in the last 12 month grew by 4%.

Zimmer Biomet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Zimmer Biomet's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zimmer Biomet's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Zimmer Biomet Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Zimmer Biomet M&A Activity

Zimmer Biomet acquired XXX companies to date.

Last acquisition by Zimmer Biomet was on XXXXXXXX, XXXXX. Zimmer Biomet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Zimmer Biomet Investment Activity

Zimmer Biomet invested in XXX companies to date.

Zimmer Biomet made its latest investment on XXXXXXXX, XXXXX. Zimmer Biomet invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).